You are here

Our science / Clinical Trials / Find a Trial / NCT01260311

Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder

Back to Search Print Save as PDF Bookmark Trial

NCT01260311

Last updated on December 6, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Mary Johnston Hospital, Inc.
Tondo, Manila, 1000 Philippines
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Over Active Bladder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Over-active bladder

- Prescribed with Fesoterodine

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Hypersensitivity

- Urinary retention

NCT01260311
Pfizer
Completed
Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Similar Trials

Bacterial Infections, Staphylococcal Vaccines, Active Immunotherapy, Staphylococcal Skin Infections, Staphylococcal Infections
An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults
NCT01018641
All Genders
18+
Years
Multiple Sites
Active Non-segmental Vitiligo
A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects
NCT03715829
All Genders
18+
Years
Multiple Sites
Overactive Urinary Bladder
A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.
NCT01302054
All Genders
18+
Years
Multiple Sites
Overactive Bladder Syndrome
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
NCT00220376
All Genders
18+
Years
RTP, North Carolina
Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder
Post Marketing Surveillance To Assess The Safety And Efficacy Of Fesoterodine (Toviaz) On Filipino Patients Diagnosed With Over-Active Bladder
This is an observational study and will determine the safety profile of fesoterodine in Filipino patients prescribed the drug. This is in compliance with the requirements of the Philippine Food and Drug Administration.
Sampling method is not applicable in this study. Only patients prescribed Fesoterodine will be enrolled.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients diagnosed with Over-active bladder
Over Active Bladder
Drug: Fesoterodine
Any dose of Fesoterodine
Other Name: Toviaz
Patients prescribed with Fesoterodine
Patients diagnosed with Over-active bladder and prescribed with fesoterodine.
Intervention: Drug: Fesoterodine
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
508
October 2013
October 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Over-active bladder
  • Prescribed with Fesoterodine

Exclusion Criteria:

  • Hypersensitivity
  • Urinary retention
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Philippines
 
 
NCT01260311
A0221085
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2014

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now